In order to enable the most accurate detection of early stage cancer, GRAIL is conducting one of the largest clinical study programs ever pursued in genomic medicine. We are collaborating with leading community and academic medical centers to conduct studies enrolling tens of thousands of people to identify the patterns required to detect many types of cancer, and studies enrolling hundreds of thousands of people to confirm the clinical validity and utility of GRAIL’s products.
Interested in participating in one of our groundbreaking studies? See if you are eligible below and sign up here to receive updates.
Are you a clinical research center interested in collaborating with GRAIL on a study? Please contact firstname.lastname@example.org.
Circulating Cell-Free Genome Atlas Study (CCGA)
The purpose of the CCGA study is to characterize the landscape of cell-free nucleic acid (cfNA) profiles in individuals with and without cancer. The observational CCGA study will enroll at least 7,000 individuals with cancer and 3,000 individuals without cancer, interrogating the biology of both tumor biopsy tissue samples and the circulating, tumor-derived nucleic acids in blood. cfNAs in the blood are an emerging biomarker for earlier cancer detection. GRAIL and its collaborators will collect clinical outcomes on the enrolled participants for at least 5 years. The result will be a detailed atlas of cancer genetics that GRAIL will use to support its product development goals. The database, upon analysis, may be expanded to additional enrollment in specific cancers or healthy individuals.
Medical centers of Cleveland Clinic, Guardian Research Network, Hartford HealthCare Cancer Institute (a member of the Memorial Sloan Kettering Cancer Alliance), Mayo Clinic (Minnesota, Arizona, and Florida), Memorial Sloan Kettering, Sylvester Comprehensive Cancer Center, and sites of US Oncology Network.
The study will enroll at least 7,000 cancer subjects with multiple types of malignancy and at least 3,000 representative subjects without a clinical diagnosis of cancer. Cancer subjects with a new diagnosis and no prior systemic therapy will be recruited. All eligible subjects must be 20 years or older and able to provide written consent to all study procedures.
The purpose of the STRIVE Study is to train and validate a test to detect breast cancer, and to train and develop a pan-cancer test to detect multiple cancers at early stages. STRIVE is a multi-center, longitudinal, prospective, observational study that will enroll up to 120,000 women at the time of their screening mammogram.
Mayo Clinic and Sutter Health.
Women undergoing screening mammography at medical centers throughout the Sutter Health system in Northern California, and Mayo Clinic. Mayo Clinic locations include Rochester, Minnesota; Jacksonville, Florida; and Phoenix, Arizona; as well as the Mayo Clinic Health System Franciscan Healthcare locations in La Crosse and Onalaska, Wisconsin. Participation is by invitation only.